Published in Cytokine on November 01, 1992
Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med (2010) 5.36
Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol (2008) 2.47
Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol (2007) 2.02
Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects. J Neuroeng Rehabil (2010) 1.14
Vitamin D in inflammatory diseases. Front Physiol (2014) 1.10
A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol (2008) 1.09
Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int (2004) 1.07
A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporos Int (2004) 1.00
Vitamin D receptor gene polymorphisms are associated with obesity and inflammosome activity. PLoS One (2014) 0.91
Predicted vitamin D status and incidence of tooth loss and periodontitis. Public Health Nutr (2013) 0.88
Serum and dietary vitamin D and cardiovascular disease risk in elderly men: a prospective cohort study. Nutr Metab Cardiovasc Dis (2011) 0.87
Relationship between vitamin D deficiency and cardiovascular disease. World J Cardiol (2013) 0.83
Dietary vitamin D deficiency in rats from middle to old age leads to elevated tyrosine nitration and proteomics changes in levels of key proteins in brain: implications for low vitamin D-dependent age-related cognitive decline. Free Radic Biol Med (2013) 0.83
Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. World J Gastroenterol (2014) 0.83
The pleiotropic effect of vitamin d. ISRN Nephrol (2013) 0.82
Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.82
Cardiovascular risk assessment in children with chronic kidney disease. Pediatr Nephrol (2012) 0.81
Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin d deficiency: an exploratory, double blind, randomised controlled trial. PLoS One (2014) 0.81
Is vitamin D deficiency a risk factor for ischemic heart disease in patients with established cardiovascular disease? 10-year follow-up of the Nova Scotia Health Survey. Int J Cardiol (2011) 0.81
Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis. PLoS One (2015) 0.81
Vitamin D and bone health: potential mechanisms. Nutrients (2010) 0.81
Vitamin d and cardiovascular disease. Curr Treat Options Cardiovasc Med (2012) 0.80
Does vitamin D deficiency contribute to erectile dysfunction? Dermatoendocrinol (2012) 0.79
Vitamin D and delirium in critically ill patients: a preliminary investigation. J Crit Care (2012) 0.79
Vitamin D receptor genetics on extracellular matrix biomarkers and hemodynamics in systolic heart failure. J Cardiovasc Pharmacol Ther (2014) 0.78
Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol (2013) 0.78
Vitamin D3 supplementation does not modify cardiovascular risk profile of adults with inadequate vitamin D status. Eur J Nutr (2015) 0.76
Subclinical cardiovascular disease markers and vitamin D deficiency in non-dialysis chronic kidney disease patients. Arch Med Sci (2016) 0.75
High Vitamin D Consumption Is Inversely Associated with Cardiovascular Disease Risk in an Urban Mexican Population. PLoS One (2016) 0.75
Serum 25-Hydroxyvitamin D Concentration Is Independently Inversely Associated with Insulin Resistance in the Healthy, Non-Obese Korean Population. Diabetes Metab J (2016) 0.75
Calcium-Vitamin D Co-supplementation Affects Metabolic Profiles, but not Pregnancy Outcomes, in Healthy Pregnant Women. Int J Prev Med (2016) 0.75
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect (2001) 2.50
Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis (2004) 2.25
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis (2008) 2.21
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 2.21
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1991) 2.09
Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J Med Chem (1998) 2.06
Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis (2011) 2.04
Mediators of immunity: lymphokines and monokines. Adv Immunol (1980) 1.99
Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia (2002) 1.93
Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest (2009) 1.82
Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun (1990) 1.81
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother (1999) 1.77
Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol (1987) 1.74
Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol (1991) 1.70
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.70
Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia (2005) 1.69
Immunological features of kala-azar. Am J Trop Med Hyg (1978) 1.61
Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia (2013) 1.59
Bicycle exercise enhances plasma IL-6 but does not change IL-1 alpha, IL-1 beta, IL-6, or TNF-alpha pre-mRNA in BMNC. J Appl Physiol (1985) (1994) 1.57
Cyclosporin for polymyositis. Lancet (1984) 1.55
Evaluation of Staph ID 32 system and Staph-Zym system for identification of coagulase-negative staphylococci. J Clin Microbiol (1995) 1.53
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) (2007) 1.53
Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology (1991) 1.52
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun (1990) 1.51
Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol (1993) 1.51
Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis (2007) 1.51
Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun (1993) 1.50
Treatment of chronic endogenous uveitis with fusidic acid. Lancet (1991) 1.50
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest (1994) 1.48
Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol (1997) 1.47
Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab (2014) 1.45
Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients. Trans R Soc Trop Med Hyg (1994) 1.45
Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia (1986) 1.42
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler (2008) 1.42
Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia (2007) 1.42
Immunohistological detection of interleukin I-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo. Br J Dermatol (1988) 1.41
Random amplified polymorphic DNA for the differentiation of Leishmania donovani isolates from Sudan. Trans R Soc Trop Med Hyg (1996) 1.41
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol (1998) 1.40
Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun (2000) 1.39
The challenge of multidisciplinary research: improving diabetic pregnancy together. Neth J Med (2013) 1.39
[Diabetes mellitus: simple classification and corresponding treatment]. Ned Tijdschr Geneeskd (2006) 1.38
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology (2005) 1.37
Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun (1984) 1.37
Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy (1985) 1.37
Effect of cyclosporin A on human neutrophil and monocyte function. Scand J Immunol (1985) 1.35
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS (2000) 1.33
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood (1998) 1.27
Interleukin 6 primes human neutrophil and monocyte oxidative burst response. Immunol Lett (1989) 1.26
Abuse and timing of use of antibiotics in acute otitis media. Arch Otolaryngol (1974) 1.24
Structure-activity studies: in vitro antileishmanial and antimalarial activities of anthraquinones from Morinda lucida. Planta Med (1999) 1.24
Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol (1989) 1.23
Blood monocyte and neutrophil functions in the acquired immune deficiency syndrome. Scand J Immunol (1986) 1.22
Virulence factors of Pseudomonas aeruginosa. Antibiot Chemother (1971) (1987) 1.21
Accepting kidneys from older living donors: impact on transplant recipient outcomes. Am J Transplant (2011) 1.20
Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett (1991) 1.19
The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis (1997) 1.18
Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax (2009) 1.17
Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob Agents Chemother (2001) 1.17
Impact of postprandial glycaemia on health and prevention of disease. Obes Rev (2012) 1.17
Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis. J Infect Dis (1991) 1.17
Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis. Rheumatol Int (1985) 1.16
Validity of histopathological grading of articular cartilage from osteoarthritic knee joints. Ann Rheum Dis (1999) 1.16
Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab (2010) 1.16
Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother (1994) 1.16
Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol (1994) 1.16
IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol (1989) 1.14
Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinol (Copenh) (1986) 1.14
Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother (1993) 1.14
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab (2012) 1.14
Suppression of parasite-specific response in Plasmodium falciparum malaria. A longitudinal study of blood mononuclear cell proliferation and subset composition. Scand J Immunol (1986) 1.14
Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol (2000) 1.14
Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med (2007) 1.14
The longitudinal association between glycaemic control and health-related quality of life following insulin therapy optimisation in type 2 diabetes patients. A prospective observational study in secondary care. Qual Life Res (2011) 1.13
Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS (1999) 1.12
The use of a water-soluble formazan complex to quantitate the cell number and mitochondrial function of Leishmania major promastigotes. Parasitol Res (1994) 1.12
Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys Res Commun (1997) 1.12
Evidence that the effect of physical exercise on NK cell activity is mediated by epinephrine. J Appl Physiol (1985) (1991) 1.11
The polymerase chain reaction can reveal the occurrence of naturally mixed infections with Leishmania parasites. Acta Trop (1994) 1.11
Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol (1999) 1.11
Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother (1994) 1.11
The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today (1996) 1.10
Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol (1999) 1.10
The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother (1995) 1.10
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia (2012) 1.09
Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res (1994) 1.09
Enhanced inhibition of in vitro multiplication of Plasmodium falciparum by stimulated human polymorphonuclear leucocytes. Clin Exp Immunol (1984) 1.09
Central nervous system effects of the neurohypophyseal hormones and related peptides. Front Neuroendocrinol (1993) 1.09
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol (2014) 1.08
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ (2006) 1.08